Bardají Bofill Manel
- Nuestros servicios
Mammary Gland Diseases: Carcicoma
Breast carcinoma is the most common cancer in women in the United States, and since 1940 the age-adjusted incidence has increased; It is currently diagnosed in one in nine Americans during their lifetime. The death rate from breast cancer is second only to lung cancer.
Its cause is likely to be multifactorial. Female sex is a predisposing factor, since only one male shows breast carcinoma for every 100 women diagnosed.
The incidence increases with age. It begins after age 20 and reaches a stable level (plateau) around menopause, then increases net after that change. Genetic factors are important in 15% of cases, and are most noticeable in women whose mother had carcinoma in both breasts before menopause. England and Wales have the highest national breast cancer mortality and Japan the lowest.
The highest risk is related to nulliparity and the first pregnancy in the last years of fertility. Estrogens induce breast cancer in mice, but no theory of induction by hormones or birth control pills has been substantiated in humans.
Among the risk factors that have been proposed are obesity, abundant consumption of animal fats and viral factors transmitted by breast milk.
The natural course of the disease has been cited in studies since the end of the last century, at Middlesex Hospital, London, in which the median survival in 250 untreated women was 2.7 years; Survival was calculated based on the description of the onset of the first symptoms.
The five-year survival was 18% and the decennial 3.76%. Necropsies showed that 95% of women died of breast carcinoma and of them 75% had breast ulcers. Biological features of breast cancer: typical scirrhosal adenocarcinoma begins in the superoexternal quadrant (45%) of the left breast (60%) and it takes 30 duplications from the single-cell stage, for a period of five to eight years to reach a palpable size (1 cm in diameter).
Metastases arise when the tumor is 0.5 cm in diameter and the prognosis is adversely influenced by the number of axillary lymph nodes affected. With the aforementioned enlargement fibrosis shortens the Cooper's ligament and there is the characteristic depression or dimpling of the skin.
Systemic spread is most common to lungs (65%), bone (56%), and liver (56%).
The diagnostic investigation should be done in an orderly manner. In any suspicious lesion, aspiration biopsy should be performed and then by partial (incisional) removal, in the direction of the skin folds (periareolar), or as a convenient resource in case of possible segmental resection or subsequent mastectomy. Staging can be done before definitive treatment and includes a chest x-ray and liver function tests. Skeletal x-rays and bone scans are not required when there are no specific symptoms.
- Adjuvant treatment
Standard postoperative adjuvant therapy in women with nodal involvement, premenopausal or perimenopausal phase, includes administration of cyclophosphamide, metrotrexate, and 5-fluorouracil (FMC) for six months. Variations include the addition of vincristine and predinisone or doxorubicin.
Postmenopausal women with lymph node involvement and estrogen receptor (ER) negativity benefit from chemotherapy. Those with lymph node involvement and receptor positivity may receive the antiestrogen tamoxifen.
Subgroups of stage I patients of any age at risk of recurrence, such as those with lymphatic invasion, high-grade tumors, or those with high-stage fraction or aneuploid DNA, may also be eligible for adjuvant chemotherapy.
Adjuvant radiotherapy is used postoperatively only in people with a high possibility of local recurrence or in patients undergoing breast-conserving surgery.
- Prognosis
Early breast cancer: five-year survival in stage I women is 95% and for stage II women 80%, with a local recurrence of 6% using adjuvant treatment as indicated. "High-risk" individuals have tumors with poor cytologic differentiation, lymphatic and vessel invasion, unsatisfactory cincunscription, a high market rate with thymidine (an increased number of cells in mitosis), and estrogen receptor negativity (50% on average).
The prognosis for stage III disease has increased by 20% to 40% at five years, with the advent of adjuvant therapy. Many of these patients may receive chemotherapy preoperatively. Stage IV disease still shows less than 10% survival at five years.
Inflammatory carcinoma (IIIb), previously considered the deadliest of all breast carcinomas, shows a five-year survival of about 30% through serial treatment of multiple modalities.
Women in whom breast cancer is discovered during pregnancy or lactation tend to be diagnosed at a later stage of the disease, compared to peers of equal age, perhaps because of the difficulty of assessing and reviewing the larger mammary glands. They should be treated as directed by the stage of your disorder.
Morning | Afternoon | |
---|---|---|
Monday | 09.00 - 13.00 h | 16.00 - 20.00 h |
Tuesday | 09.00 - 13.00 h | 16.00 - 20.00 h |
Wednesday | 09.00 - 13.00 h | 16.00 - 20.00 h |
Thursday | 09.00 - 13.00 h | 16.00 - 20.00 h |
Friday | 09.00 - 13.00 h | 16.00 - 20.00 h |